Penalizing drug makers in Medicare for raising prices too fast would likely not cause them to hike prices in the commercial market, according to a study published Friday (Sept. 11) in the Journal of the American Medical Association . Both the Senate Finance-passed and House-passed drug pricing bills would make drug companies pay rebates to Medicare when they raise prices faster than inflation, and critics of the legislation say inflation penalties could have the perverse effect of encouraging drug companies...